Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer

Pei Rong Ding1, Xin An1, Rong Xin Zhang1, Fang Yu1, Li Ren Li1, Gong Chen1, Xiao Wu1, Zhen Lü1, Jun Lin1, Ling Heng Kong1, De Sen Wan1, Zhi Zhong Pan1
1State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People’s Republic of China

Tóm tắt

Từ khóa


Tài liệu tham khảo

Gill S, Loprinzi CL, Sargent DJ, Thome SD et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22(10):1797–1806

Quasar Collaborative G, Gray R, Barnwell J, McConkey C et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604):2020–2029

Schippinger W, Samonigg H, Schaberl-Moser R, Greil R et al (2007) A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 97(8):1021–1027

Cianchi F, Messerini L, Comin CE, Boddi V et al (2007) Pathologic determinants of survival after resection of T3N0 (Stage IIA) colorectal cancer: proposal for a new prognostic model. Dis Colon Rectum 50(9):1332–1341

Benson AB, Schrag D, Somerfield MR, Cohen AM et al (2004) American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–3419

Walsh SR, Cook EJ, Goulder F, Justin TA et al (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91(3):181–184

Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A et al (2008) Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 34(1):55–60

Kishi Y, Kopetz S, Chun YS, Palavecino M et al (2009) Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614–622

American Joint Committee on Cancer (2002) AJCC cancer staging manual, 6th edn. Springer-Verlag, New York

O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American joint committee on cancer sixth edition staging. J Natl Cancer Inst 96(19):1420–1425

Sarraf KM, Belcher E, Raevsky E, Nicholson AG et al (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137(2):425–428

Cho H, Hur HW, Kim SW, Kim SH et al (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58(1):15–23

Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP et al (2008) Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 97(6):513–518

Gomez D, Farid S, Malik HZ, Young AL et al (2008) Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 32(8):1757–1762

Gal R, Sadikov E, Sulkes J, Klein B et al (2004) Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. Dis Colon Rectum 47(7):1216–1224

Dotor E, Cuatrecases M, Martinez-Iniesta M, Navarro M et al (2006) Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24(10):1603–1611

Westra JL, Schaapveld M, Hollema H, de Boer JP et al (2005) Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 23(24):5635–5643

Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349(3):247–257

Barrier A, Boelle PY, Roser F, Gregg J et al (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24(29):4685–4691

Uen YH, Lu CY, Tsai HL, Yu FJ et al (2008) Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncol 15(8):2120–2128

Ohtani H (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 7:4

Ownby HE, Roi LD, Isenberg RR, Brennan MJ (1983) Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 52(1):126–130

Strieter RM, Burdick MD, Mestas J, Gomperts B et al (2006) Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42(6):768–778

Halazun KJ, Hardy MA, Rana AA, Woodland DC et al (2009) Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 250(1):141–151

Swanson RS, Compton CC, Stewart AK, Bland KI (2003) The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10(1):65–71

Vather R, Sammour T, Zargar-Shoshtari K, Metcalf P et al (2009) Lymph node examination as a predictor of long-term outcome in Dukes B colon cancer. Int J Colorectal Dis 24(3):283–288

Sarli L, Bader G, Iusco D, Salvemini C et al (2005) Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 41(2):272–279

Wright FC, Law CH, Last L, Khalifa M et al (2003) Lymph node retrieval and assessment in stage II colorectal cancer: a population-based study. Ann Surg Oncol 10(8):903–909

Law CH, Wright FC, Rapanos T, Alzahrani M et al (2003) Impact of lymph node retrieval and pathological ultra-staging on the prognosis of stage II colon cancer. J Surg Oncol 84(3):120–126

Tanaka M, Hashiguchi Y, Ueno H, Hase K et al (2003) Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum 46(8):1054–1059

Wang LM, Kevans D, Mulcahy H, O’Sullivan J et al (2009) Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 33(1):134–141